[House Hearing, 108 Congress]
[From the U.S. Government Printing Office]

AGRICULTURE, RURAL DEVELOPMENT, FOOD AND DRUG ADMINISTRATION, AND RELATED AGENCIES APPROPRIATIONS FOR 2004

HEARINGS

BEFORE A

SUBCOMMITTEE OF THE

COMMITTEE ON APPROPRIATIONS

HOUSE OF REPRESENTATIVES

ONE HUNDRED EIGHTH CONGRESS
FIRST SESSION

_____

SUBCOMMITTEE ON AGRICULTURE, RURAL DEVELOPMENT, FOOD AND DRUG ADMINISTRATION, AND RELATED AGENCIES
HENRY BONILLA, Texas, Chairman

JAMES T. WALSH, New York
JACK KINGSTON, Georgia
GEORGE R. NETHERCUTT, Jr., Washington
TOM LATHAM, Iowa
JO ANN EMERSON, Missouri
VIRGIL H. GOODE, Jr., Virginia
RAY LaHOOD, Illinois

MARCY KAPTUR, Ohio
ROSA L. DeLAURO, Connecticut
MAURICE D. HINCHEY, New York
SAM FARR, California
ALLEN BOYD, Florida

NOTE: Under Committee Rules, Mr. Young, as Chairman of the Full Committee, and Mr. Obey, as Ranking Minority Member of the Full Committee, are authorized to sit as Members of all Subcommittees.

Henry E. Moore, Martin P. Delgado, Maureen Holohan, and Joanne L. Perdue, Staff Assistants

_____

PART 5

AGRICULTURAL PROGRAMS

Page

Food and Drug Administration..... 1
Farm Credit Administration..... 892
Commodity Futures Trading Commission..... 1103

_____

Printed for the use of the Committee on Appropriations

_____

U.S. GOVERNMENT PRINTING OFFICE
86-642 WASHINGTON : 2003

COMMITTEE ON APPROPRIATIONS

C. W. BILL YOUNG, Florida, Chairman

RALPH REGULA, Ohio
JERRY LEWIS, California
HAROLD ROGERS, Kentucky
FRANK R. WOLF, Virginia
JIM KOLBE, Arizona
JAMES T. WALSH, New York
CHARLES H. TAYLOR, North Carolina
DAVID L. HOBSON, Ohio
ERNEST J. ISTOOK, Jr., Oklahoma
HENRY BONILLA, Texas
JOE KNOLLENBERG, Michigan
JACK KINGSTON, Georgia
RODNEY P. FRELINGHUYSEN, New Jersey
ROGER F. WICKER, Mississippi
GEORGE R. NETHERCUTT, Jr., Washington
RANDY ``DUKE'' CUNNINGHAM, California
TODD TIAHRT, Kansas
ZACH WAMP, Tennessee
TOM LATHAM, Iowa
ANNE M. NORTHUP, Kentucky
ROBERT B. ADERHOLT, Alabama
JO ANN EMERSON, Missouri
KAY GRANGER, Texas
JOHN E. PETERSON, Pennsylvania
VIRGIL H. GOODE, Jr., Virginia
JOHN T. DOOLITTLE, California
RAY LaHOOD, Illinois
JOHN E. SWEENEY, New York
DAVID VITTER, Louisiana
DON SHERWOOD, Pennsylvania
DAVE WELDON, Florida
MICHAEL K. SIMPSON, Idaho
JOHN ABNEY CULBERSON, Texas
MARK STEVEN KIRK, Illinois

DAVID R. OBEY, Wisconsin
JOHN P. MURTHA, Pennsylvania
NORMAN D. DICKS, Washington
MARTIN OLAV SABO, Minnesota
STENY H. HOYER, Maryland
ALAN B. MOLLOHAN, West Virginia
MARCY KAPTUR, Ohio
PETER J. VISCLOSKY, Indiana
NITA M. LOWEY, New York
JOSE E. SERRANO, New York
ROSA L. DeLAURO, Connecticut
JAMES P. MORAN, Virginia
JOHN W. OLVER, Massachusetts
ED PASTOR, Arizona
DAVID E. PRICE, North Carolina
CHET EDWARDS, Texas
ROBERT E. ``BUD'' CRAMER, Jr., Alabama
PATRICK J. KENNEDY, Rhode Island
JAMES E. CLYBURN, South Carolina
MAURICE D. HINCHEY, New York
LUCILLE ROYBAL-ALLARD, California
SAM FARR, California
JESSE L. JACKSON, Jr., Illinois
CAROLYN C. KILPATRICK, Michigan
ALLEN BOYD, Florida
CHAKA FATTAH, Pennsylvania
STEVEN R. ROTHMAN, New Jersey
SANFORD D. BISHOP, Jr., Georgia
MARION BERRY, Arkansas

ANDER CRENSHAW, Florida

James W. Dyer, Clerk and Staff Director

[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]

W I T N E S S E S

	Page
McClellan, Mark	1
Reyna, M. M.	892
Weber, J. M.	1
Weems, K. N.	1

I N D E X

Food and Drug Administration

	Page
Advisory Committees	96
Agriculturally Derived Pharmaceuticals	44
AIDS Activities	98
AIDS Therapies	98
Animal Drugs and Feeds:	
Animal Drug Review	101, 247, 248
BSE-Prevention Activities	114
BSE-Resources	116, 119
BSE-Vaccine Safety	118
User Fees, Animal Drug	45, 235, 269
Antibiotic/Antimicrobial Resistance:	
Antimicrobial Resistance Activities	102
Antimicrobial Resistance Resources	101
Guidance for Industry	104, 262
Package Inserts, Antibiotic	262
Proposed Rule	262
Withdrawal of Product Approval	104
Biographical Sketches:	
Dr. Mark McClellan, M.D., Ph.D	32
Mr. Kerry N. Weems	33
Mr. Jeffrey M. Weber	34
Biologics:	
Blood Safety	108
Blood Safety--Donation Deferrals	113
Blood Safety--West Nile Virus	110, 112

Blood Safety Resources..... 114
CBER/CDER Consolidation..... 213
PDUFA..... 197
PDUFA Financial Report..... 203
PDUFA Performance Goals..... 201
Plasma Therapies..... 250
Bovine Spongiform Encephalopathy (BSE):
Prevention Activities..... 114
Resources.....116, 119
Vaccine Safety.....118, 226
Budget:
Congressional Justification..... 285
Budget in Brief..... 290
Budget in Brief to Reflect FY 2003 Appropriation, Revised 618
Foods..... 367
Human Drugs..... 391
Biologics..... 426
Animal Drugs and Feeds..... 447
Devices and Radiological Health..... 468
National Center for Toxicological Research..... 491
Office of Regulatory Affairs..... 501
Other Activities..... 531
Rent..... 549
Buildings and Facilities..... 554
Contingency Fund..... 125
Crosswalk from Current Estimate to Actuals..... 120
Counter Terrorism Funding..... 209
Current Services..... 125
Expiring Authorizations..... 208
FY 2004 Budget Request..... 285
FY 2004 Budget Initiatives by Program.....123, 212
FY 2003 Savings..... 62
Funding to Meet Statutory Requirements..... 165
Research..... 205
Reductions and Cost Savings..... 61
Unauthorized Appropriations..... 208
Buildings and Facilities:
CDER Move..... 215
Consolidation Plan and Status..... 168
Los Angeles Laboratory..... 194
Chronic Diseases Undertreated..... 90
Closing Comments..... 91
Color Certification.....35, 231
Congressional Directives:
Adverse Events Reporting System--Medical Devices..... 158
Biotechnology..... 152
Blood Safety and Adequacy..... 145
Blood Supply.....147, 154
Building International Regulatory Capacity..... 148
Dietary Supplement Study..... 142
Drug Patent Listing..... 143
Ephedra Products..... 142
Food Allergies..... 142
Foodborne Illness from Raw Shellfish..... 151
Food Safety..... 150
Generic Drugs..... 153
Genetically Engineered Foods..... 138

Ginseng..... 140
HACCP Compliance..... 152
Intravenous Immune Globulin..... 144
Juice HACCP Implementation..... 138
Listeria Risk Assessment..... 139
Medical Devices--Class II..... 157
Office of Women's Health..... 159
Preventing Allergic Reactions to Natural Rubber Latex in the Workplace..... 156
Reused Medical Devices..... 157
Seafood Safety..... 150
Shellfish Safety..... 139
Standards of Identity--Milk Protein Concentrate..... 153
Tissue Safety Rules..... 156
Congressional Reports--Status..... 160
Counter Terrorism:
Funding, Counter Terrorism..... 72
Food Safety.....38, 277
FDA Initiatives and Timeline..... 75
First Amendment Issues..... 260
Foods/Food Safety:
Acrylamide..... 273
Allergens..... 284
Application Review Statutory Requirement and Performance Level..... 163
Bioengineered Foods.....229, 252
Budget, Food Safety.....77, 174
CFSAN Adverse Event Reporting System (CAERS)..... 227
Codex Alimentarius Commission..... 125
Counter Terrorism.....38, 277
Dietary Supplements.....133, 251
News Release--Proposed Regulation..... 93
Egg Safety.....167, 279
Ephedra.....57, 134, 136
Foodborne Illness, Source of..... 59
Food Safety.....76, 175, 265
Food Safety Definition..... 174
Food Safety Initiative.....174, 180
Gel Candies..... 230
HAACP-Juice or Seafood..... 205
Homeland Security and Food Safety..... 83
Irradiation.....71, 263
Labeling.....171, 232
Listeria Monocytogenes.....139, 275
Mercury Levels in Seafood..... 279
Milk Protein Concentrate..... 281
Organic Food Labeling..... 52
Pesticides..... 53
Recalls.....172, 254, 278
Seafood Safety/Shellfish Safety.....205, 257, 272
Single Food Agency..... 82
Threat Assessment Report..... 260
Good Manufacturing for the 21st Century..... 49
Human Drugs:
Adverse Events--Recalls..... 105
Adverse Drug Information, Source of..... 82
Adverse Medical Event Activity Funding..... 105

Agriculturally Derived Pharmaceuticals..... 247
AIDS Drug Approval Times..... 98
Application Review Statutory Requirement and Performance Level..... 163
Aseptic Processing of Drugs..... 49
Best Pharmaceuticals for Children Act..... 259
CDER/CBER Consolidation..... 213
Cost of Drug Advertising.....55, 87, 91, 241
Cost of Prescription Drugs..... 56
Cuban Pharmaceutical Industry..... 84
Drug Application Review Times.....61, 161
Federal Subsidies to Drug Companies..... 70
Gender Based Trials..... 270
Generic Drugs:
Approvals..... 183
Cost of Pharmaceuticals..... 60
Education Campaign.....41, 267
Proposed Rule.....39, 42, 75, 267
Proposed Rule Timeline..... 40
Review Times.....41, 74, 183, 268, 270
Patents and Generic Drugs..... 73
Resources.....182, 184, 261, 270
Grapefruit/Drug Interactions..... 78
Guaifenesin.....69, 236
Importation/Re-importation of Drugs.....50, 57
Internet Drug Sales.....192, 244
Marketing and Advertising, Drug.....55, 87, 91, 241
Marketing, Drug and Enforcement.....75, 85
Medical Gas..... 250
Mental Illness.....62, 68, 257
Misuse of Pharmaceuticals..... 60
Orange Book..... 234
Overmedicated and Undermedicated Society..... 88
Over the Counter Drugs (OTC).....239, 248, 249
Patient Safety/Adverse Events.....107, 224
PDUFA..... 197
PDUFA Financial Report..... 203
PDUFA Performance Goals..... 201
Pediatric Rule.....45, 54, 221
Personal Importation Policy..... 193
Pre- and Postmarketing of Drugs..... 81
Prescription Drug Benefits for Seniors..... 249
Re-importation of Drugs.....50, 244
Safety of Approved Drugs..... 80
Imports and Inspections:
Food Inspections--Domestic..... 170
Foreign Facility, Inspection of.....78, 265
Funding to Meet Statutory Requirements..... 165
High Risk Food Inspections..... 170
Imported Food Inspections..... 170
Inventory of Firms.....171, 187
Laboratory Capacity..... 233
Line Entries, Imports..... 187
Personal (Prescription Drug) Importation Policy..... 193
Re-importation of Drugs.....50, 244
Risk-based Inspections and New Approach..... 223
Safety of Imported Products..... 73

Tampering..... 206
International Activities:
Implementation of the US-EU Mutual Recognition Agreement..... 191
International Cooperative Agreements.....189, 265
International Health Regulations..... 265
Priorities in International Activities..... 190
Introduction of Witnesses..... 1
Justification of Estimates for Appropriations Committees:
Organization Chart, Current..... 288
Organization Chart, Proposed..... 289
Budget in Brief..... 290
Performance Plan Summary..... 340
Appropriations Language and Analysis..... 344
Base Resources..... 345
Summary of Change..... 347
Crosswalk for All Purpose Table--Budget Authority Changes.... 348
Crosswalk to Summary of Change--Program Level..... 351
Budget Authority by Activity (All Purpose Tables)..... 352
Comparable Tables..... 355
Program Justifications..... 367
Exhibits..... 557
Glossary..... 612
Resubmission of Budget in Brief..... 617
Management Activities:
Consolidation..... 219
Office of Legislative Affairs..... 215
Reorganizations..... 215
Medical Devices and Radiological Products:
510(k) Applications..... 126
Application Review Statutory Requirement and Performance Level..... 163
Approval Times..... 128
Devices--Establishment Types..... 130
Devices--Extramural Projects..... 131
Devices--Regulatory Actions and Enforcement..... 129
Devices Resources.....128, 129
Mammography Quality Standards Act (MQSA)..... 195
MedSuN..... 227
Regulatory Actions..... 129
User Fees, Medical Device.....47, 51, 268, 269
User Fees, Medical Device and Budget Authority..... 51
Office of Criminal Investigations..... 196
Opening Remarks by Dr. McClellan, FDA Commissioner..... 2
Patents and Generic Drugs..... 73
Patient Safety/Adverse Events.....107, 224
Pediatric Rule.....45, 54, 221
Pediatric Rule Codification..... 54
Pediatric Rule Litigation..... 46
Performance Plan:
Performance Plan..... 684
Performance Plan Executive Summary..... 688
Performance Plan Report by Programs/Areas..... 732
Performance Plan Appendices..... 858
Personnel:
Hiring Rate..... 195
New Hires..... 195
Questions Submitted for the Record:

Mr. Bonilla..... 96
Mr. Nethercutt..... 244
Mr. Latham..... 247
Mr. LaHood..... 250
Ms. Kaptur..... 254
Ms. DeLauro..... 265
Mr. Obey..... 281
Mrs. Lowey..... 284
Public Perception of FDA..... 256
Recalls:
Products Recovered in a Recall.....172, 254, 278
Recall Authority..... 255
Rent..... 204
Research..... 205
Statement by Dr. McClellan, M.D., Ph.D., DFA Commissioner..... 6
United Financial Management System (UFMS)..... 218
U.S. Code Citations..... 207
Warning Letters, Procedures for Clearing..... 264
Witness List..... 1
Women's Health:
Demographic Database on Clinical Trials..... 270
Hormone Replacement Therapy.....35, 45, 266
Hormone Replacement Therapy Recommendations..... 37

Farm Credit Administration

Annual Performance Plan..... 973
Audit..... 915
Bio--Michael M. Reyna..... 907
Budget Trends..... 945
Compensation Study..... 933
Equipment..... 934
Examination Issues..... 915
Farm Credit System:
Annual Report..... 931
Financial Condition.....899, 912
Market Share..... 929
Senior Officer Compenastion.....913, 920
Structure..... 911
Farm Credit System Insurance Corporation..... 922
FCA:
Operations..... 908
Staffing..... 908
Federal Agricultural Mortgage Corporation.....900, 924
Fiscal Year 2002 Accomplishments..... 894
Fiscal Year 2004 Budget Request..... 903
Fiscal Year 2004 Proposed Budget and Annual Performance Plan..... 940
Litigation Involving FCA..... 919
Loans for Designated Parties..... 930
Major Accomplishments and Projects During FY 2002..... 951
Performance and Accountability Report Fiscal Year 2002..... 990
Questions Submitted by Chairman Bonilla..... 908
Risk Assessment..... 915
Role and Responsibility of the Farm Credit Administration..... 893
Sole Source Contracts and Consulting Services Contracts..... 918
Status of Regulations..... 934
Summaries of Studies..... 938

Testimony--Michael M. Reyna..... 892
Young, Beginning, and Small Farmers..... 928

Commodity Futures Trading Commission

Advisory Committees..... 1126
Agricultural Trade Options Rules..... 1106
Agricultural Trading Volume..... 1107
Appropriations and Authorized FTEs..... 1125
Budget Reduction, Impact of..... 1133
Carryover Funds..... 1103
Civil and Administrative Proceedings..... 1118
Civil Monetary Penalties..... 1112
Civil Monetary Penalties Imposed and Collected..... 1112
Contract Designation Applications, Pending..... 1119
Contract Market Designations and Rules Reviews Under Fast Track Review..... 1129
Contracts Approved, New..... 1119
Cooperative Enforcement and Regulation..... 1117
Counter-Terrorism..... 1136
Derivatives Clearing Organizations..... 1140
Dual Trading..... 1109
    Dual Trading Fraud..... 1110
    Dual Trading Investigations..... 1110
Emergency Supplemental:
    Expenditures, Description of..... 1133
    Status of FY 2003 Funds..... 1132
Employment, FY 2003 Monthly On-Board..... 1134
Energy Markets..... 1140
Enforcement Investigations..... 1116
Equipment Costs..... 1136
Firm Failures..... 1111
Foreign Assistance..... 1113
Foreign Currency Transactions..... 1138
Inspector General Audits..... 1103
International Affairs, Activities of the Office of..... 1127
Introducing Brokers, Registered..... 1126
New Authorities Under the CFMA, Impact of..... 1144
NFA Disciplinary Actions..... 1107
OMB Request..... 1103
Opt Out of Segregation..... 1132
Other Services Costs..... 1136
Pay Parity..... 1135
President's Working Group on Financial Markets..... 1110
Rental Costs..... 1136
Retention Bonuses..... 1137
Reparations Program..... 1128
Rule Enforcement Program..... 1109
SEC and CFTC Cooperative Efforts..... 1108
Security Futures Products..... 1131
Security Futures Products, CFTC-SEC Joint Oversight of..... 1143
Self-Policing Activities..... 1111
Service Fees..... 1107
Single-Stock Futures Regulations..... 1132
Staffing Level, Reduced:
    Plans to Reach..... 1135
    Use of Attrition in Reaching..... 1135

Studies Required by the CFMA:
    Intermediary Study Pursuant to the CFMA..... 1137
    Study Required by Section 125 of CFMA..... 1145
Travel Budget..... 1113
Unauthorized Appropriations..... 1131
USA Patriot Act..... 1141

?